» Articles » PMID: 23363047

The G-quadruplex Ligand, SYUIQ-FM05, Targets Proto-oncogene C-kit Transcription and Induces Apoptosis in K562 Cells

Overview
Journal Pharm Biol
Specialties Pharmacology
Pharmacy
Date 2013 Feb 1
PMID 23363047
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Context: N'-(7-Fluoro-5-N-methyl-10H-indolo[3,2-b]quinolin-5-ium)-N,N-dimethylpropane-1,3-diamine iodide (SYUIQ-FM05) is a semi-synthetic derivative of cryptolepine which is from Cryptolepis sanguinolenta (Lindl.) Schlechter (Periplocaeae). This ligand inhibits telomerase activity by stabilizing the G-quadruplex structure and induces growth arrest in cancer cells.

Objective: The anticancer activity of SYUIQ-FM05 via inhibiting c-kit transcription was investigated in leukemic cells.

Materials And Methods: The cytotoxicity of SYUIQ-FM05 in K562 cells was evaluated using a cell viability assay and flow cytometry (FCM) at 0.4, 2.0, 10.0 and 20.0 nM. Under the same concentrations of SYUIQ-FM05 or 100 nM imatinib mesylate (IM), quantitative polymerase chain reaction (Q-PCR) investigated transcription of c-kit and bcl-2, and western blotting analyzed the expression levels of c-Kit, total mitogen-activated protein kinase kinases (MEKs), phospho-MEK (p-MEK), total extracellular regulated protein kinases (ERKs), phospho-ERK (p-ERK), Bcl-2 and Bax.

Results: SYUIQ-FM05 inhibited cellular growth with an IC(50) of 10.83 ± 0.05 nM in K562 cells. c-Kit transcription was suppressed 2.69-, 4.39-, 7.71- and 10.52-fold at 0.4, 2.0, 10.0 and 20.0 nM SYUIQ-FM05, respectively, which produced proportional loss of total c-Kit protein except IM. Both SYUIQ-FM05 and IM downregulated p-MEK and p-ERK. Furthermore, bcl-2 transcription was suppressed 1.58- and 1.86-fold at 10.0 and 20.0 nM SYUIQ-FM05, respectively, but 0.4 and 2.0 nM SYUIQ-FM05 had no effect. A decrease in Bcl-2 and an increase in Bax appeared in these treated cells.

Discussion And Conclusion: These findings demonstrate that SYUIQ-FM05 could induce apoptosis in a leukemic cell line through inhibiting c-kit transcription, which supports the anticancer potency of SYUIQ-FM05 in c-Kit-positive leukemic cells.

Citing Articles

Selective Recognition of G-Quadruplex by Structural Tuning of Heteroaromatic Scaffolds and Side Chains.

Fatma K, Thumpati P, Panda D, Velayutham R, Dash J ACS Med Chem Lett. 2024; 15(3):388-395.

PMID: 38505840 PMC: 10945540. DOI: 10.1021/acsmedchemlett.3c00537.


Recent Advances in the Chemistry and Pharmacology of Cryptolepine.

Shnyder S, Wright C Prog Chem Org Nat Prod. 2021; 115:177-203.

PMID: 33797643 DOI: 10.1007/978-3-030-64853-4_4.


G-quadruplexes: a promising target for cancer therapy.

Kosiol N, Juranek S, Brossart P, Heine A, Paeschke K Mol Cancer. 2021; 20(1):40.

PMID: 33632214 PMC: 7905668. DOI: 10.1186/s12943-021-01328-4.


Whole-Transcriptome Profiling of Canine and Human in Vitro Models Exposed to a G-Quadruplex Binding Small Molecule.

Zorzan E, Elgendy R, Giantin M, Dacasto M, Sissi C Sci Rep. 2018; 8(1):17107.

PMID: 30459395 PMC: 6244004. DOI: 10.1038/s41598-018-35516-y.


Carbazole Derivatives' Binding to c-KIT G-Quadruplex DNA.

Gluszynska A, Juskowiak B, Kuta-Siejkowska M, Hoffmann M, Haider S Molecules. 2018; 23(5).

PMID: 29747481 PMC: 6099540. DOI: 10.3390/molecules23051134.